Post Hoc SOLARIS Data Support Stabilization and Remission With Subcutaneous Olanzapine

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

Teva Pharmaceutical (TEVA) presented data on ecopipam, an investigational drug for pediatric Tourette syndrome, showing sustained tic reduction in clinical trials. The drug received FDA Priority Review and Orphan Drug designation. Teva's stock is currently trading at $39.37, up 0.15%.

Teva Pharmaceutical Industries presented new data on ecopipam, an investigational treatment for pediatric Tourette syndrome, at a medical congress. The data included safety and efficacy results from an 8-week treatment period and an ongoing open-label extension study.

Sanofi & Regeneron expanded their immunology partnership for up to $8B. Novo Nordisk acquired rights to a drug from Hengrui Pharma for up to $2.6B. Telix Pharmaceuticals to acquire ITM Isotope for up to $2.35B. Merck licensed a cancer drug from SciBrunch for up to $2.13B. Genentech partnered with Earendil Labs for up to $1.5B. GSK acquired a hepatic program from Wave Life Sciences. Lundbeck may acquire Xeris Biopharma.

Teva (TEVA) reported that 69.8% of 292 patients in a pooled analysis showed clinically meaningful tic improvement within 8 weeks of using ecopipam, an investigational treatment for pediatric Tourette syndrome. An 18-month interim analysis of an ongoing open-label extension study found a 45.6% mean reduction in tic severity scores with no new safety signals. The FDA has granted ecopipam Priority Review and Orphan Drug designation.

Teva (TEVA) reported that ecopipam, an investigational drug for Tourette syndrome, reduced pediatric tic relapse risk by 50% vs. placebo in a Phase 3 trial (HR: 0.5; P=0.008). The FDA granted Priority Review and Orphan Drug designation for its pediatric use. Common side effects included somnolence and headache, but no significant weight gain or metabolic issues were observed.